US Bancorp
SRNE

US Bancorp’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

US Bancorp’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,000
Closed -$28.4K – 4249
2022
Q4 		$28.4K Sell
32,000
-9,880
-24% -$13.1K ﹤0.01% 2816
2022
Q3 		$66K Buy
41,880
+4,846
+13% +$11K ﹤0.01% 2396
2022
Q2 		$74K Sell
37,034
-4,776
-11% -$8.26K ﹤0.01% 2384
2022
Q1 		$97K Buy
41,810
+9,941
+31% +$31K ﹤0.01% 2296
2021
Q4 		$149K Buy
31,869
+6,269
+24% +$38.9K ﹤0.01% 2098
2021
Q3 		$195K Sell
25,600
-240
-0.9% -$2.04K ﹤0.01% 1980
2021
Q2 		$251K Buy
25,840
+2,350
+10% +$18.7K ﹤0.01% 1875
2021
Q1 		$195K Buy
23,490
+5,863
+33% +$61.9K ﹤0.01% 1928
2020
Q4 		$120K Buy
17,627
+581
+3% +$4.67K ﹤0.01% 2128
2020
Q3 		$190K Buy
17,046
+5,392
+46% +$49.3K ﹤0.01% 1792
2020
Q2 		$74K Buy
+11,654
New +$44.6K ﹤0.01% 2251

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

US Bancorp's SRNE Position: Q1 2023 in Review

US Bancorp sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 32,000 shares — an estimated $28.4K sold.

US Bancorp first reported a position in SRNE in Q2 2020 and held it in 11 quarters. The position peaked at $251K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • US Bancorp reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • US Bancorp sold 32,000 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $28.4K.
  • US Bancorp first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
  • US Bancorp's Sorrento Therapeutics, Inc. position peaked at $251K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.